Medical Research Journals

MedicalResearch.com Interview with: [caption id="attachment_55163" align="alignleft" width="133"]Dr-Monik Jimenez Dr. Jimenez[/caption] Monik Carmen Jimenez, Sc.D Assistant Professor of Medicine Brigham and Women's Hospital MedicalResearch.com: What is the background for this study? Response: We wanted to get a comprehensive picture of the epidemiology of COVID-19 in carceral facilities that included jails and was not restricted solely to prisons. We utilized publicly available data collected in Massachusetts, pursuant to a court order. These data included prison and jail systems and were used to calculate rates of confirmed cases of COVID-19 and testing rates among incarcerated individuals. We were also able to compare those to changes in the population size within each system.

MedicalResearch.com Interview with: [caption id="attachment_55114" align="alignleft" width="200"]Jeremy Samuel Faust, M.D., M.S., M.A., FACEP Brigham & Women's Hospital Department of Emergency Medicine Division of Health Policy and Public Health Instructor, Harvard Medical School President, Roomful of Teeth Vocal Arts Project (www.roomfulofteeth.org) Dr. Faust[/caption] Jeremy Samuel Faust, M.D., M.S., M.A., FACEP Brigham & Women's Hospital Department of Emergency Medicine Division of Health Policy and Public Health Instructor, Harvard Medical School President, Roomful of Teeth Vocal Arts Project (www.roomfulofteeth.org)  MedicalResearch.com: What is the background for this study? What are the main findings? Response: We sought to compare the initial covid-19 outbreak in NYC to the peak of the 1918 H1N1 pandemic in that same city. We found that the covid-19 pandemic was associated with more than 70% as many deaths per capita (monthly) as 1918 H1N1 was. But because baseline mortality rates are about 1/2 of what they were a century ago, death rates were over 400% of usual rates in March and April of this year compared to recent years, while 1918 was "merely" over 280% of usual death rates from prior years leading up to it.

MedicalResearch.com Interview with: [caption id="attachment_55134" align="alignleft" width="130"]Professor Aneel K Aggarwal, PhD Pharmacological Sciences and Oncological Sciences Icahn School of Medicine at Mount Sinai Dr. Aggarwal[/caption] Professor Aneel K Aggarwal, PhD Pharmacological Sciences and Oncological Sciences Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: DNA polymerase ζ  (Pol ζ) is the crucial enzyme that allows cells to cope with DNA damage resulting from exposure to environmental and industrial carcinogens and to other daily genotoxic stresses. At the same time, Pol ζ has emerged as an important target for discovery of therapeutics in the treatment of chemotherapy-resistant cancers.  MedicalResearch.com: What are the main findings?   Response: We have succeeded in resolving the 3-D atomic structure of the complete Pol ζ enzyme using cryo-electron microscopy.

MedicalResearch.com Interview with: [caption id="attachment_55140" align="alignleft" width="142"]Pinar Karaca-Mandic, PhD Professor, Finance Department  Arthur Williams Jr. Professor of Healthcare Risk Management   Academic Director, Medical Industry Leadership Institute (MILI) Carlson School of Management University of Minnesota Dr. Karaca Mandic[/caption] Pinar Karaca-Mandic, PhD Professor, Finance Department Arthur Williams Jr. Professor of Healthcare Risk Management Academic Director, Medical Industry Leadership Institute (MILI) Carlson School of Management University of Minnesota MedicalResearch.com: What is the background for this study? Response: Several studies have highlighted disparities in COVID-19 infection rates and deaths. Less is known about disparities in hospitalizations. Reports from the Centers for Disease Control showed that in the nation overall, non-Hispanic Blacks, Hispanics and American Indian Alaska Native persons have substantially higher rates of COVID-19 hospitalization. Our study extends this work by providing a state-by-state analysis of race/ethnic prevalence of cumulative COVID-19 hospitalizations and comparing this prevalence to ethnic/racial composition of each state’s population. Through our University of Minnesota Covid-19 hospitalization tracking project (https://carlsonschool.umn.edu/mili-misrc-covid19-tracking-project) we collect data every day from state department of health websites, and we started collecting information on race/ethnicity breakdown of the hospitalizations as soon as states started reporting such data. During our study period, between April 30 and June 24, 12 states reported cumulative hospitalizations by race/ethnicity. By the end of our study, our data from these 12 states represented almost 50,000 hospitalizations. 

MedicalResearch.com Interview with: [caption id="attachment_55124" align="alignleft" width="160"]Maryam M. Asgari, MD MPH Professor Department of Dermatology, Massachusetts General Hospital Department of Population Medicine, Harvard Medical School Dr. Asgari[/caption] Maryam M. Asgari, MD MPH Professor Department of Dermatology, Massachusetts General Hospital Department of Population Medicine, Harvard Medical School MedicalResearch.com: What is the background for this study? What are Topical Calcineurin Inhibitors used for?  Response: Topical calcineurin inhibitors (TCIs) are FDA approved for the treatment of atopic dermatitis (though they are used off-label to treat a wide range of inflammatory conditions of the skin, including psoriasis, seborrheic dermatitis, and contact dermatitis).  There are currently two drugs available – tacrolimus and pimecrolimus – both of which carry a black box label warning users about the potential for increased skin cancer risk.  The risk associated with keratinocyte carcinoma, the most common cancer (defined as basal cell carcinoma and squamous cell carcinoma), remains poorly defined because findings from large-scale post-marketing surveillance studies are lacking. 

MedicalResearch.com Interview with: [caption id="attachment_55105" align="alignleft" width="150"]Dr-Morayma Reyes Gil Dr. Reyes Gil[/caption] Morayma Reyes Gil M.D., Ph.D. Director of hematology and Coagulation Labs Associate Professor, Pathology Montefiore Medical Center and Albert Einstein School of Medicine Bronx, NY 10467 MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Antiphospholipid Syndrome is an entity caused by autoantibodies that cause arterial and venous thrombosis as well as miscarriages. During the COVID-19 pandemic, we tested 187 patients for Lupus anticoagulant (LA); 68 turned out to be COVID positive. 30 of the 68 COVID-positive patients were found to be positive for LA by the DRVVT test, and 17 of them were also determined to be positive by the hexagonal phospholipid neutralization STACLOT-LA test. Importantly, of the 30 patients who were LA positive, 19 had documented thrombosis (arterial and venous), an event rate of 63%, as compared with a rate of 34% (p = .03) for LA-negative patients. We also checked CRP, an inflammatory marker known to affect the hexagonal phospholipid neutralization STACLOT-LA test. Although the mean CRP level was higher in patients testing positive for LA by DRVVT (14.4 vs 7.5 mg/dL; P < .01), patients with thrombosis did not have significantly higher CRP levels than those with no thrombosis. Hence, we adjusted for CRP, and LA was found to be independently associated with thrombosis (odds ratio, 4.39; 95% CI, 1.45-14.57; p= .01). No statistically significant difference was found by anticoagulation at the time of thrombosis, gender, race, ethnicity, ventilation, and mortality between patients who tested LA positive vs. negative. 

MedicalResearch.com Interview with: [caption id="attachment_55120" align="alignleft" width="133"]Elizabeth Webb, M.P.H Physiotherapy Department Calvary Public Hospital Bruce Bruce, Australia Elizabeth Webb[/caption] Elizabeth Webb, M.P.H Physiotherapy Department Calvary Public Hospital Bruce Bruce, Australia MedicalResearch.com: What is the background for this study? Response: Our study showed that in patients with a history of leg swelling (chronic edema), compression therapy by a skilled lymphedema therapist reduced the risk of infection in the leg (cellulitis) by a huge 77%. With up to 47% of patients experiencing recurrence of cellulitis in their legs within 3 years, this result is a game-changer in terms of our approach to managing patients with leg swelling and recurrent cellulitis. Until now, the use of prophylactic antibiotics to prevent cellulitis has been the only evidence-based practice. We know however, there are many reasons why avoidance of antibiotics is important within our community.

MedicalResearch.com Interview with: [caption id="attachment_55111" align="alignleft" width="147"]Prakash Deedwania, MD, FACC,FAHA,FASH,FHFSA,FESC Professor of Medicine, UCSF School of Medicine, San Francisco Dr. Deedwania[/caption] Prakash Deedwania, MD, FACC,FAHA,FASH,FHFSA,FESC Professor of Medicine, UCSF School of Medicine, San Francisco MedicalResearch.com: What is the background for this study? What are the main findings? Response: This paper describes the findings form the FOURIER study, a very large study evaluating the efficacy of evolocumab, a PCSK9 inhibitor in patients with metabolic syndrome and preexisting atherosclerotic cardiovascular disease (ASCVD) who were already being treated with statins. In this largest study of its kind of 27,000 patients we found that 60% of patients with ASCVD had metabolic syndrome. We also found that the presence of metabolic syndrome identified a higher risk of future cardiac & coronary events in these patients despite them receiving maximum tolerated doses of statin. Furthermore, study treatment with evolocumab was efficacious in reducing the increased risk during the median follow up of nearly 3 years . Unlike treatment with statins there was no risk of new-onset diabetes with evolocumab, which was generally well tolerated. What was interesting thatpatients without metabolic syndrome had much less benefit with PCSK9 inhibition. These findings suggest that the presence of metabolic syndrome can help the clinicians identify the ASCVD patients who are most likely to benefit from treatment with PCSK9 inhibitors. This will be of great help for the cost containment of therapeutic strategy as PCSK9 inhibitors as a class are still quite expensive drugs.

MedicalResearch.com Interview with: Caspar van der Made, MD Resident in Internal Medicine, PhD-student Alexander Hoischen, PhD Geneticist, Assistant professor, Departments of Human Genetics and Internal Medicine Radboud University Medical enter Nijmegen, The Netherlands  First author Caspar van der Made is a resident in Internal Medicine and PhD-student on the topic of immunogenomics. Alexander Hoischen is geneticist with a special focus on the application of genomic technologies in primary immunodeficiencies and last author of this study. MedicalResearch.com: What is the background for this study?   Response: This study was initiated to investigate the presence of monogenic factors that predispose young individuals to develop a severe form of COVID-19. It has become clear that several general risk factors such as obesity, hypertension and diabetes mellitus increase the risk of developing severe coronavirus disease. However, even though differences in interindividual genetic make-up are thought to influence the immune response to SARS-CoV-2, such specific genetic risk factors had not yet been identified. We therefore chose to study young brother pairs (sharing half of their genomes) without any general risk factors that nevertheless contracted severe COVID-19. We hypothesized these highly selected case series may offer the most optimal chance of identifying a (possible X-linked) primary immunodeficiency specific to COVID-19.

MedicalResearch.com Interview with: [caption id="attachment_55057" align="alignleft" width="133"]Jeffrey J. Walline, OD PhD Associate Dean for Research The Ohio State University Columbus, OH 43210-1240 Dr. Walline[/caption] Jeffrey J. Walline, OD PhD Associate Dean for Research The Ohio State University Columbus, OH 43210-1240  MedicalResearch.com: What is the background for this study? Response: Greater amounts of nearsightedness are related to higher risks of sight-threatening complications in adulthood, so anything we can do to slow the progression of nearsightedness in childhood can have meaningful benefits in the future. As the prevalence of nearsightedness increases worldwide and affects approximately 1/3 of the people in the United States, a treatment that provides clear vision AND slows the progression of nearsightedness can have a profound effect.

MedicalResearch.com Interview with: [caption id="attachment_55070" align="alignleft" width="132"]Karina W. Davidson, PhD, MA Senior Vice President of Research, Northwell Health Director, Center for Personalized Health, Feinstein Institutes for Medical Research Dean of Academic Affairs & Professor, Feinstein Institutes for Medical Research Donald and Barbara Zucker Professor in Health Outcomes, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Dr. Davidson[/caption] Karina W. Davidson, PhD, MA Senior Vice President of Research, Northwell Health Director, Center for Personalized Health, Feinstein Institutes for Medical Research Dean of Academic Affairs & Professor, Feinstein Institutes for Medical Research Donald and Barbara Zucker Professor in Health Outcomes, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell MedicalResearch.com: What is the background for this study? What are the main findings? Response: New York was epicenter for COVID-19 at the height of the pandemic, and Northwell Health, the largest health system in New York, did everything in its power to care for our sick community members but also care for and protect our frontline health care providers (HCPs) and 72,000 employees. We were fortunate enough to have not run out of PPE – from masks to gowns. Through our employee health team we were able to offer free antibody screenings and through the Northwell Health Research Consortium and the Feinstein Institutes for Medical Research we looked to use the data collected from our consented employees to determine the prevalence of antibodies. We designed the study to not only identify the presence of antibodies but also key factors like demographics, in what capacity our providers worked on the frontlines and if they suspected infection. Our data helped identify the best practices Northwell Health – from PPE to care procedures - and others nationwide would need to do to keep our frontline workers safe. Key takeaways from the research show that from April 20 to June 23, of the final consented sample of health care providers (40,329), 13 percent (5,523) tested positive for antibodies. The positive sample pool included 28.4 percent (11,468) nurses and 9.3 percent (3,746) physicians.

MedicalResearch.com Interview with: [caption id="attachment_55053" align="alignleft" width="160"]Ty J. Gluckman, M.D., FACC Providence St Joseph Health Portland, Oregon Dr. Gluckman[/caption] Ty J. Gluckman, M.D., FACC Providence St Joseph Health Portland, Oregon MedicalResearch.com: What is the background for this study? Response: In spite of significant decreases in the incidence of coronary artery disease, an estimated 800,000 Americans are expected to be diagnosed with an acute myocardial infarction (AMI) this year.  For large numbers of these patients, substantial benefit is afforded by early diagnosis and treatment.  Accordingly, multiple campaigns have been launched over time to increase public awareness about the symptoms and signs of AMI and the need to seek immediate medical attention. The COVID-19 pandemic has profoundly changed health care delivery worldwide.  While early attention was disproportionately focused on efforts to “flatten the curve”, recent reports have revealed a disturbing finding—a substantial decrease in the hospitalization rate for AMI.  Most worrisome among potential reasons for this has been reluctance of patients with an AMI to seek medical attention out of fear that they become infected with SARS-CoV-2. To better understand the impacts associated with this, we performed a retrospective, cross-sectional study of all AMI hospitalizations in a large multistate health care system (Providence St. Joseph Health).  We sought to define changes in AMI case rates, patient demographics, cardiovascular comorbidities, treatment approaches and in-hospital outcomes during the pandemic.

MedicalResearch.com Interview with: [caption id="attachment_55045" align="alignleft" width="200"]Moritz Gerstung PhD Group Leader: Computational cancer biology EMBL-European Bioinformatics Institute Dr. Gerstung[/caption] Moritz Gerstung PhD Group Leader: Computational cancer biology EMBL-European Bioinformatics Institute MedicalResearch.com: What is the background for this study? Response: We have learned a lot in the last ten years about the molecular nature about various cancers thanks to the resources created by TCGA, ICGC and many other initiatives. Similarly, digital pathology has progressed hugely due to new AI algorithms. Yet it hasn’t been explored deeply how a cancer’s genetic makeup and its histopathological appearance are related. Here computers can be very helpful as they can process large amounts of digital microscopy slide images and test whether there are any recurrent histopathological patterns in relation to hundreds or thousands of genetic and other molecular abnormalities. 

MedicalResearch.com Interview with: [caption id="attachment_54986" align="alignleft" width="200"]Taylor Heald-Sargent, M.D., Ph.D. Ann & Robert H. Lurie Children’s Hospital Chicago Dr. Heald-Sargent[/caption] Taylor Heald-Sargent, M.D., Ph.D. Ann & Robert H. Lurie Children’s Hospital Chicago MedicalResearch.com: What is the background for this study? Response: Given the ongoing debate around the ability of children to transmit SARS-CoV-2, we noticed that our clinical data could address one of the prevalent assumptions.  Some people postulated that the reason children have less severe infections with SARS-CoV-2 is because they are not able to replicate virus as much as adults and therefore may not transmit as readily. 

MedicalResearch.com Interview with: [caption id="attachment_55014" align="alignleft" width="200"]Harvey W. Kaufman, MD, MBA, FCAP Senior Medical Director, Medical Informatics Quest Diagnostics Needham, MA Harvey Kaufman[/caption] Harvey W. Kaufman, MD, MBA, FCAP Senior Medical Director, Medical Informatics Quest Diagnostics Needham, MA  MedicalResearch.com: What is the background for this study? Response: The COVID-19 pandemic has disrupted routine healthcare and in particular cancer screenings.  We documented the impact on patients who were newly identified by cancer in the early months of the pandemic by analysis of Quest Diagnostics data. MedicalResearch.com: What are the main findings?  Response: We saw a 46% decline in newly identified patients with six common types of cancer.  In accordance to healthcare recommendations, many patients didn’t receive mammograms, colonoscopies, low-dose CT scans, and avoided physician visits for minor complaints.  When these patients return, some will present with more advanced stages of cancer than they would have without the disruption of the pandemic. 

MedicalResearch.com Interview with: [caption id="attachment_55005" align="alignleft" width="200"]Nasim B. Ferdows, Ph.D. Assistant Professor, Department of Health Administration and Policy Hudson College of Public Health The University of Oklahoma Health Sciences Center Oklahoma City, OK  Dr. Ferdows[/caption] Nasim B. Ferdows, Ph.D. Assistant Professor, Department of Health Administration and Policy Hudson College of Public Health The University of Oklahoma Health Sciences Center Oklahoma City, OK MedicalResearch.com: What is the background for this study? Response: This half a century study of US senior men and women who died between 1968 and 2016 shows how disparities in the Black and White mortality of older US citizens have changed over time, as well as how the racial disparities differ in rural, suburban and urban areas.

MedicalResearch.com Interview with: Jane Daniels PhD Professor of Clinical Trials, Faculty of Medicine & Health Sciences School of Medicine University of Nottingham MedicalResearch.com: What is the background for this study? MedicalResearch.com: What are the main findings? [caption id="attachment_54976" align="alignleft" width="200"]One example of a large fibroid-Wikipedia image One example of a large fibroid-Wikipedia image[/caption] Response: Uterine fibroids are the most common non-cancerous tumour in women of childbearing age. They are associated with heavy bleeding, lower chances of having children and reduced quality of life. Traditional surgical options were either to remove the fibroids (myomectomy) or completely remove the womb. A newer approach, known as uterine artery embolization, involves blocking the blood supply to the fibroids in the womb. Fibroids may be associated with infertility and problems during pregnancy, including miscarriage and preterm birth. As more women are having children at a later age, fibroids are becoming more of an issue for them and safe and effective fertility sparing treatments are needed. Both treatments improve quality of life, but myomectomy will provide greater benefit to women on average. MedicalResearch.com: What should readers take away from your report? Response: This study is the largest to date comparing women treated with either myomectomy or uterine-artery embolization for their fibroids. It was completed in hospitals across the UK, and included a substantial number of women of African-Caribbean ethnicity, who are more likely have bothersome fibroids, so we can be confident that the findings are important and relevant. Women, including those desiring a future pregnancy, should be provided with the evidence generated by the FEMME trial to enable to make a fully informed decision regarding their fibroid treatment.

MedicalResearch.com Interview with: [caption id="attachment_54971" align="alignleft" width="160"]Frank Wharam, MD, MPH Department of Population Medicine Harvard Medical School and Harvard Pilgrim Healthcare Institute Boston, MA 02215 Dr. Wharam[/caption] Frank Wharam, MD, MPH Department of Population Medicine Harvard Medical School and Harvard Pilgrim Healthcare Institute Boston, MA 02215 MedicalResearch.com: What is the background for this study? Response:  There is substantial concern that high-deductible health plans increase people’s risk of major adverse health events such as heart attack and stroke. No studies have examined this question. This study examines the effects of a transition to a high-deductible health plan on the risk of major adverse cardiovascular outcomes (myocardial infarction and stroke). The study group included individuals with risk factors for cardiovascular disease who were continuously enrolled in low-deductible (<$500) health plans during a baseline year followed by up to 4 years in high-deductible (≥$1000) plans after an employer-mandated switch. The matched control group included individuals with the same risk factors who were contemporaneously enrolled in low-deductible plans.  We examined time to first major adverse cardiovascular event, defined as myocardial infarction or stroke. 

MedicalResearch.com Interview with: [caption id="attachment_54919" align="alignleft" width="200"]Rabin Medical Center Rabin Medical Center[/caption] Daniel Shepshelovich MD Professor, Department of Medicine Rabin Medical Center Israel MedicalResearch.com: What is the background for this study? Response: The study was initiated as part of a research project aiming to assess the quality of post marketing surveillance of various medical interventions. This includes drugs (file:///C:/Users/danielshep/Downloads/jamainternal_ross_2019_en_190008.pdf), medical devices (accepted to a leading medical journal, still under embargo) and additional studies in specific settings (e.g. cancer drugs, immune-modulating drugs). Through this perspective, vaccines are clearly safer as a group than drugs or medical devices, with significantly less post-marketing safety issues, most of which were not clinically important, and a more effective post-marketing surveillance program.

MedicalResearch.com Interview with: [caption id="attachment_54915" align="alignleft" width="133"]Daniel Hal Solomon, MD, MPH Associate Physician, Brigham and Women's Hospital Professor of Medicine, Harvard Medical School Brigham and Women's Hospital Department of Medicine Rheumatology, Immunology Boston, MA 02115 Dr. Solomon[/caption] Daniel Hal Solomon, MD, MPH Associate Physician, Brigham and Women's Hospital Professor of Medicine, Harvard Medical School Brigham and Women's Hospital Department of Medicine Rheumatology, Immunology Boston, MA 02115 Editor’s note: Prolia® is the trade name for denosumab.  MedicalResearch.com: What is the background for this study? Response: We conducted this study to assess whether delays in denosumab (injections were associated with an increased risk of fractures. In a prior study, we found that the improvements in bone mineral density were reduced among patients who delayed injections.

MedicalResearch.com Interview with: [caption id="attachment_54938" align="alignleft" width="200"]Dr. Valentina Puntmann Dr. Puntmann[/caption] Assoc. Prof. Dr. Valentina Puntmann, MD, PhD, FRCP Deputy Head Goethe CVI Fellowship Programme Lead Consultant Physician, Cardiologist and Clinical Pharmacologist Institute for Experimental and Translational Cardiovascular Imaging DZHK Centre for Cardiovascular Imaging - Goethe CVI Department of Cardiology, Division of Internal Medicine University Hospital Frankfurt, Germany MedicalResearch.com: What is the background for this study? Response: Patients who recently recovered from COVID19 have been identified through the testing centre and invited to be screened for cardiac involvement with MRI. Importantly, they have not come to us because of having heart problems. In fact, none of them thought that they had had anything wrong with the heart.  They were mostly healthy, sporty and well prior to their illness. A considerable proportion had been infected while on skiing vacations.

MedicalResearch.com Interview with: [caption id="attachment_54896" align="alignleft" width="132"] Dr. Jagsi[/caption] Reshma Jagsi, M.D., D.Phil. Newman Family Professor and Deputy Chair Department of Radiation Oncology Director of the Center for Bioethics and Social Sciences in Medicine University of Michigan  MedicalResearch.com: What is the background for this study? Response: Hospitals and health care institutions often rely on philanthropy for support to be able to pursue their missions to serve the public health. Little is known about public perspectives, which are needed to inform ethical guidelines.

MedicalResearch.com Interview with: Mayu Nishimura Department of Ophthalmology and Vision Sciences Director of Research Kindergarten Vision Screening Program  MedicalResearch.com: What is the background for this study? child-looking-vision Response: Children's visual problems are difficult to identify without formal tests but most parents do not realize the importance of early eye checks nor are they aware that well-child visits to the family doctor/pediatrician are not enough. We are researchers at McMaster University (Hamilton, ON) and SickKids Hospital (Toronto, ON) who examined if it is possible to implement a vision screening program for kindergartners in diverse Ontario communities. Below are the main findings:
  • We screened nearly 5000 kindergarten children in 15 communities and found that 11% of screened children had a visual problem, with 2/3 of the children being identified for the first time.
  • There was great support for the program from the children, parents, teachers, and optometrists.
  • Screening required 15-20 minutes per child and cost $10/child.
  • When parents received a letter permitting them to opt out of screening, 4% did so. When parents were required to return a signed letter to opt in, 30% did not.
  • Referral rates varied across schools but were higher for children in junior kindergarten (average 53%) than children in senior kindergarten (average 34%).
  • Successful treatment depends on the parents’ awareness of the importance of eye exams and glasses, and access to optometrists and glasses without worrying about costs.

MedicalResearch.com Interview with: [caption id="attachment_54863" align="alignleft" width="200"]Dr.Altuna Akalin PhD Head of Bioinformatics and Omics Data Science Platform Berlin Institute for Medical Systems Biology (BIMSB) Max Delbrück Center for Molecular Medicine (MDC) Berlin, Germany Dr. Akalin[/caption] Dr.Altuna Akalin PhD Head of Bioinformatics and Omics Data Science Platform Berlin Institute for Medical Systems Biology (BIMSB) Max Delbrück Center for Molecular Medicine (MDC) Berlin, Germany  MedicalResearch.com: What is the background for this study? Where does the word Janggu come from?  Response: Deep learning applications on genomic datasets used to be a cumbersome process where researchers spend a lot of time on preparing and formatting data before they even can run deep learning models. In addition, the evaluation of deep learning models and the choice of deep learning framework were also not straightforward. To streamline these processes, we developed Janggu. With this framework, we are aiming to relieve some of that technical burden and make deep learning accessible to as many people as possible. Janggu is named after a traditional Korean drum shaped like an hourglass turned on its side. The two large sections of the hourglass represent the areas Janggu is focused: pre-processing of genomics data, results visualization and model evaluation. The narrow connector in the middle represents a placeholder for any type of deep learning model researchers wish to use. 

MedicalResearch.com Interview with: [caption id="attachment_54859" align="alignleft" width="181"]Frederick Hayden MD Stuart S Richardson Professor Emeritus of Clinical Virology Professor Emeritus of Medicine Division of Infectious Diseases and International Health University of Virginia Dr. Hayden[/caption] Frederick Hayden MD Stuart S Richardson Professor Emeritus of Clinical Virology Professor Emeritus of Medicine Division of Infectious Diseases and International Health University of Virginia  MedicalResearch.com: What is the background for this study? Response: Although primary prevention approach for influenza infections is vaccination, vaccine efficacy is incomplete and uptake rates are variable in the population. Preventing people who have been exposed to someone with influenza from developing the disease is an important way to prevent its rapid spread, reduce the disruption to peoples' lives and, in some cases, reducing the risk of serious illness or even death.  Prior studies have shown that antivirals like oseltamivir and inhaled zanamivir can reduce the risk influenza illness in those exposed. The BLOCKSTONE study was designed to assess the efficacy of postexposure prophylaxis with a single oral dose of baloxavir for the preventing influenza in household contacts. This antiviral drug was approved first in 2018 for treatment of adults with uncomplicated influenza. 

MedicalResearch.com Interview with: [caption id="attachment_51654" align="alignleft" width="133"]Manja Koch Dr. oec. troph. (Ph.D. equivalent) Research Associate Department of Nutrition Harvard T.H. Chan School of Public Health Dr. Koch[/caption] Manja Koch, Ph.D., Research Associate Department of Nutrition Harvard T.H. Chan School of Public Health [caption id="attachment_51694" align="alignleft" width="150"]Majken K. Jensen, PhD Associate Professor of Nutrition Harvard T.H. Chan School of Public Health Dr. Jensen[/caption] Majken K. Jensen, Ph.D. Adjunct Professor of Nutrition Harvard T.H. Chan School of Public Health & Professor in the Department of Public Health University of Copenhagen, Copenhagen, Denmark     MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease and other dementias are highly prevalent conditions. According to the Alzheimer’s Association, 50 million people are currently living with Alzheimer’s disease or other dementias worldwide. Lower apolipoprotein E in plasma is a risk factor for dementia, but the underlying biological mechanisms are not fully understood. Thus, we investigated the role of apolipoprotein E overall and in lipoproteins with distinct metabolic functions in relation to cognitive function and dementia risk..

MedicalResearch.com Interview with: [caption id="attachment_54851" align="alignleft" width="127"]Mario Fl Gaudino MD Professor of Cardiothoracic Surgery Department of Cardiothoracic Surgery Weill Cornell Medicine  Dr. Gaudino[/caption] Mario Fl Gaudino MD Professor of Cardiothoracic Surgery Department of Cardiothoracic Surgery Weill Cornell Medicine  MedicalResearch.com: What is the background for this study? Response: The radial artery is currently used in less than 10% of CABG procedures in the US.  MedicalResearch.com: What are the main findings? Response: The JAMA paper provides convincing evidence that the use of the radial artery rather than the saphenous vein to complement the internal thoracic artery for CABG is associated with improved long-term outcomes. 

MedicalResearch.com Interview with: Zhila Semnani-Azad, Ph.D. Candidate  Department of Nutritional Sciences Faculty of Medicine, University of Toronto Toronto, ON, Canada MedicalResearch.com: What is the background for this study? Response: Dietary fructose-containing sugars have been suggested to be an important contributing factor to increased metabolic syndrome risk. Several studies have consistently shown a strong association between sugar-sweetened beverages and increased incidence of metabolic syndrome. There is little information, however, on the role of other food sources of fructose-containing sugars in the development of metabolic syndrome.